Literature DB >> 7989493

[111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?

P T Postema1, E P Krenning, R Wijngaarde, P P Kooy, H Y Oei, W A van den Bosch, J C Reubi, W M Wiersinga, H Hooijkaas, T van der Loos.   

Abstract

Visualization of malignant lymphomas and granulomatous disease is possible by [111In-DTPA-D-Phe1]octreotide scintigraphy through binding of the radioligand to somatostatin receptors on activated leukocytes. Because thyroidal and orbital tissues are infiltrated by activated leukocytes in Graves' disease, a cross-sectional study to visualize disease activity with [111In-DTPA-D-Phe1]octreotide scintigraphy was performed. A correlation between thyroidal [111In-DTPA-D-Phe1]octreotide accumulation and free T4 (disease expression) and thyroid binding-inhibiting immunoglobulins (disease activity) is present in untreated hyperthyroid Graves' disease. There is also a correlation between orbital [111In-DTPA-D-Phe1]octreotide uptake and the clinical activity score (disease activity) and total eye score (disease expression), respectively, in Graves' orbitopathy. Visualization of thyroidal and orbital Graves' disease is feasible, but further investigation is necessary to establish the role of [111In-DTPA-D-Phe1]octreotide scintigraphy in representing disease activity and expression and in predicting therapeutical outcome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989493     DOI: 10.1210/jcem.79.6.7989493

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  In vivo imaging of insulitis in autoimmune diabetes.

Authors:  A Signore; M Chianelli; M G Parisella; G Capriotti; P Giacalone; G Di Leve; R Barone
Journal:  J Endocrinol Invest       Date:  1999-02       Impact factor: 4.256

Review 2.  Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy.

Authors:  C Marcocci; M Marinò; R Rocchi; F Menconi; E Morabito; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

3.  Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.

Authors:  T-C Chang; S-L Liao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

4.  Update on advanced imaging options for thyroid-associated orbitopathy.

Authors:  Michael P Rabinowitz; Jacqueline R Carrasco
Journal:  Saudi J Ophthalmol       Date:  2012-10

5.  Somatostatin-receptor scintigraphy in Graves' orbitopathy.

Authors:  P T Postema; D J Kwekkeboom; P M van Hagen; E P Krenning
Journal:  Eur J Nucl Med       Date:  1996-06

Review 6.  Somatostatin receptor SPECT.

Authors:  Giovanna Pepe; Roy Moncayo; Emilio Bombardieri; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

7.  99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study.

Authors:  M Chianelli; S J Mather; A Grossman; R Sobnak; A Fritzberg; K E Britton; A Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-10       Impact factor: 9.236

8.  [Octreotide scintigraphy for the diagnosis of active Graves' ophthalmopathy].

Authors:  N Ardjomand; G Esche; P Fellner; S Lindner; M Panzitt; R Aigner; A Langmann
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

9.  (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO).

Authors:  Hua Sun; Xu-Feng Jiang; Shu Wang; Hao-Yan Chen; Jiao Sun; Pei-Yong Li; Guang Ning; Yong-Ju Zhao
Journal:  Endocrine       Date:  2007-06       Impact factor: 3.633

Review 10.  Recent developments in Graves' ophthalmopathy imaging.

Authors:  G J Kahaly
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.